Oncology

News

ADC Therapeutics slumps on cancer drug safety scare

Shares in ADC Therapeutics fell more than 50% after a non-Hodgkin lymphoma trial showed more deaths with its Zynlonta drug compared to a control.

News

AbbVie's ovarian cancer drug Elahere gets NHS green light

AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.

News

ASCO26: Celcuity punished as trial disappoints investors

Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.

News

ASCO26: In vivo CAR-Ts in the spotlight

Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.

News

ASCO26: After negative adcomm, AZ builds case for oral SERD

AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA's review of the drug back on track.

News

ASCO26: Symptom-tracking app helps advanced cancer patients

An app used to support people living with advanced cancer has helped them maintain quality of life, and also kept them out of hospital.

ADC Therapeutics slumps on cancer drug safety scare

AbbVie's ovarian cancer drug Elahere gets NHS green light

ASCO26: Celcuity punished as trial disappoints investors

ASCO26: In vivo CAR-Ts in the spotlight

ASCO26: After negative adcomm, AZ builds case for oral SERD

ASCO26: Symptom-tracking app helps advanced cancer patients

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks